Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2156-2162

  Shinozaki, Masaru ^a   Hoon, Dave S B ^a,c   Giuliano, Armando E ^b   Hansen, Nora M ^b   Wang, He Jing ^c   Turner, Roderick ^c   Taback, Bret ^a,b  

^a Department of Molecular Oncology ^*  (United States)

^b Joyce Eisenberg Keefer Breast Center   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID BINDING RECEPTOR BETA 2 PROTEIN; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CYTODIAGNOSIS; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; SENTINEL LYMPH NODE; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA METHYLATION; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; SENTINEL LYMPH NODE BIOPSY; TUMOR SUPPRESSOR PROTEINS;

EID: 16844383767     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1810     Document Type: Article

References (47)

1. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131:301-8.
2. Miller BA, Feuer EJ, Hankey BF. Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 1993;43:27-41.
3. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66:136-8.
4. Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998;83:1362-8.
5. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553-9.
6. Giuliano AE, Kelemen PR. Sophisticated techniques detect obscure lymph node metastases in carcinoma of the breast. Cancer 1998;83:391-3.
7. Giuliano AE. See one, do twenty-five, teach one: the implementation of sentinel node dissection in breast cancer. Ann Surg Oncol 1999;6:520-1.
8. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
9. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
10. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992;339:1245-8.
11. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
12. Taback B, Chan AD, Kuo CT, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 2001;61:8845-50.
13. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
14. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002;20:3404-12.
15. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
16. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
17. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
18. Jatoi I, Hilsenbeck SG, Clark GM, Osbome CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999;17:2334-40.
19. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
20. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
21. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
22. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43.
23. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-22.
24. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194:585-91.
25. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-7.
26. th edition New York: Springer-Verlag;2002. p. 223-40.
27. Henderson CJ, McLaren AW, Moffat GJ, Bacon EJ, Wolf CR. Pi-class glutathione S-transferase: regulation and function. Chem Biol Interact 1998;111-2:69-82.
28. Key TJ, Allen NE, Spencer EA, Travis RC. Nutrition and breast cancer. Breast 2003;12:412-6.
29. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21:3-16.
30. Lacroix A, Lippman ME. Binding of retinoids to human breast cancer cell lines and their effects on cell growth. J Clin Invest 1980;65:586-91.
31. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res 1984;44:5757-63.
32. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996;38:85-96.
33. Martinet N, Alla F, Farre G, et al. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res 2000;60:2869-75.
34. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
35. Singletary SE, Atkinson EN, Hoque A, et al. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002;8:2835-42.
36. Dragnev KH, Petty WJ, Dmitrovsky E. Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther 2003;2:S150-6.
37. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502-9.
38. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997;80:1188-97.
39. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
40. Hansen NM, Grube BJ, Te W, Brennan M, Turner RR, Giuliano A. Clinical significance of axillary micrometastases in breast cancer: how small is too small? San Francisco: American Society of Clinical Oncology; 2001. p. 24a.
41. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004;1014:155-63.
42. Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, α- and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001;18:513-20.
43. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98.
44. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.
45. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56:4063-70.
46. Mehrotra J, Vali M, McVeigh M, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004;10:3104-9.
47. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5.